Skip to search formSkip to main contentSkip to account menu
New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man
TLDR
Using considerably improved analytical methods, the kinetics and effects of clonidine were observed in healthy volunteers over periods of time more than 3 times longer than those previously reported and cannot be described by a conventional, open one or two compartment model.
View on Springer
Novel potent inhibitor of receptor-activated nonselective cation currents in HL-60 cells.
TLDR
A new compound is described, (RS)-(3, 4-dihydro-6,7-dimethoxyisoquinoline-1-gamma 1)-2-phenyl-N, N-di-[2,3,4-trimethoxyphenyl)ethyl]acetamide (LOE 908), that fully blocked these currents at 3 microM.
View on PubMed
New aspects of the clinical pharmacology of clonidine.
  • D. Arndts
  • Medicine, Biology
    Chest
  • 1 February 1983
TLDR
Using a newly developed radioimmunoassay, the pharmacokinetics and the pharmacologic effects of clonidine simultaneously are observed simultaneously in normotensive subjects following single and multiple administration of infusions, tablets, and Perlongets given in varying doses.
View on PubMed
Development of a RIA for clonidine and its comparison with the reference methods.
View on PubMed
A newly developed precise and sensitive radioimmunoassay for clonidine.
TLDR
With the radioimmunoassay applied in pharmacokinetic studies a maximal clonidine concentration in blood plasma of healthy human volunteers was determined to 0.6 ng/ml 1.5 h after oral administration of 150 micrograms.
View on PubMed
[Studies on the distribution and elimination of a proteinase inhibitor with isotope technics].
View on PubMed
Evaluation of clonidine plasma levels in man using a highly sensitive radioimmunoassay
Within the past few years the need for safe, sensitive, and specific drug determination methods has become increasingly necessary.
View via Publisher
Ω-conotoxin GVIA potently inhibits the currents mediated by P2X receptors in rat DRG neurons
View on Elsevier
Alinidine pharmacokinetics following acute and chronic dosing.
TLDR
Alinidine (N-allyl clonidine) pharmacokinetics were investigated in healthy volunteers following acute administration of 40 mg orally and intravenously (i.v.) and chronic administration of alinidine 40 mg daily and twice daily for 8 days, finding it is unlikely thatClonidine formed from al inidine contributes to the pharmacological action of alInidine.
View on PubMed
Development and quality control of a highly sensitive radioimmunoassay for alinidine.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License